Quantitative pharmacology (QP) applications in translational medicine, drug-development, and therapeutic use were crowdsourced by the ASCPT Impact and Influence initiative. Highlighted QP case studies demonstrated faster access to innovative therapies for patients through 1) rational dose selection for pivotal trials; 2) reduced trial-burden for vulnerable populations; or 3) simplified posology. Critical success factors were proactive stakeholder engagement, alignment on the value of model-informed approaches, and utilizing foundational clinical pharmacology understanding of the therapy.
Quantitative pharmacology (QP) discovers and confirms the key drug characteristics to provide clear, reproducible, and predictive evidence for optimizing drug development plans, enabling critical decisionmaking, and eventually bringing safe and effective medicines to patients. 1 These modeling approaches include empirical, semimechanistic, or quantitative systems pharmacology modeling techniques with the aim to integrate current knowledge regarding the drug, disease, and mechanism, and then to predict (interpolate or extrapolate) outcomes under new conditions such as untested doses and regimens, populations, or diseases. 2 As part of the model-informed drug discovery and development paradigm, QP methods can be employed in all phases of the drug development process from biomarker selection in translational medicine to dose/regimen selection, evidence generation for regulatory approval, and for extrapolation or pharmacoeconomic assessment during therapeutic use. 2 Application of QP has been advocated to play an important role in delivering new therapies to patients faster by increasing confidence in decision-making during drug development and by increasing efficiency through eliminating costs or reducing cycle times. However, most reports to date have summarized the return on investment of using QP approaches primarily in the domain of cost savings and efficiency gains. [2] [3] [4] Here, we describe the potential of QP approaches to accelerate patient access to innovative therapies.
Although QP approaches are ardently supported by QP practitioners and their department heads, widespread and consistent appreciation of the value of QP in bringing novel therapies quicker to patients at the right dose is still lacking in the wider community of the pharmaceutical industry and healthcare providers. We think that this gap in appreciation and adoption by the wider community of stakeholders and decision-makers can be bridged through better communication designed to convey the value of such QP approaches from a patient access and healthcare perspective, 2 coupled with wider adoption of good practices among the communities of practitioners. 5 
IMPACT AND INFLUENCE INITIATIVE
With this goal in mind, the Impact and Influence Initiative of the QP Network of the American Society for Clinical Pharmacology and Therapeutics (ASCPT) crowdsourced a compendium of case-examples demonstrating the innovative applications of QP throughout the drug development process. Thirty-seven case-examples were received and grouped into five application areas: Translational Medicine, Drug Development Decision-making, Regulatory Decision-making, Therapeutic Use, and Cost-effectiveness & Differentiation, illustrating the positive impact and tangible value of applied QP in an easily understood and educational format (details are provided in Supplementary Material). From this compendium, eight examples were identified in which QP enabled faster access to innovative medicines for patients through rational dose regimen selection for pivotal registration trials, reducing trial burden for vulnerable populations, or simplification of dosing (posology) for patients and healthcare providers during therapeutic use expansion of the novel therapy (see Table  T1 1 for details on case studies, and Figure 1 as a graphical illustration).
RATIONAL DOSE SELECTION FOR PIVOTAL REGISTRATION TRIALS
QP played a critical role in accelerating access to novel medicines by incorporating information from all available trials, allowing to select optimal doses and dosing regimens for pivotal confirmatory trials based on exposure-related benefit/risk analysis. In addition, QP approaches were utilized to seek regulatory approval for a dose that had not been tested in a pivotal trial.
Consider the case of the interleukin-17A antagonist secukinumab for the treatment of psoriasis, where mathematical modeling of integrated data from all phase I and II studies gave the team the confidence to select dosing regimens for the phase III trials that had not been tested previously. Phase III confirmed the positive benefitrisk for the QP-informed dosing regimens, which were subsequently approved. A key learning from this successful application of QP was that both long-term planning, as well as involvement and commitment from colleagues with a range of skill-sets (clinicians, statisticians, biologists, modelers, etc.) was required for building and applying the model, in combination with building trust with the stakeholders and decision makers about the predictive capabilities of the model.
Similarly, for naloxegol, a selective opioid receptor antagonist for treatment of opioid-induced constipation, an untested lower dose than what had previously been tested was brought into phase III based on a QP approach that predicted an improved benefit-risk for the lower dose. The modeling approach here reduced the number of doses tested and increased the probability of success of the pivotal trial.
In an even more impactful example, pembrolizumab, a potent antibody against PD-1 receptor, was approved in the early days for ipilimumab-na€ ıve metastatic melanoma patients at a 2 mg/kg Q3W dose. This dose, however, was not studied in the pivotal trial, but justified through integrated analysis of the totality of the data from available trials at the time. Since then, the label has been updated with respect to a fixed dose posology of 200 mg and additional indications.
In each of these three case examples, application of a model-informed approach for dose selection and justification enabled patients to have access to the medicine earlier ($0.5-1 year, estimated by case-study owners) than using a solely data-driven approach.
REDUCING TRIAL BURDEN FOR VULNERABLE POPULATIONS
Special populations such as pediatrics have immensely benefited from QP with model- What is the optimal dosing regimen to be used in phase III?
Model-based integration of phase I/II data allowed the selection of two dosing regimens for phase III which had not been tested previously. Phase III confirmed the positive benefit-risk for those doses and dosing regimens, and these were subsequently approved (150 and 300 mg once weekly for 5 injections, followed by a dose every 4 weeks).
Without M&S, a suboptimal regimen would have been selected that would have led to an inferior benefit-risk profile, or required further iterations of finding optimal dosing regimen. How should the dramatic increase of clearance due to UGT-1A1 maturation be addressed in in a 6-week dosing regimen for neonates? The dramatic increase in raltegravir clearance as the result of UGT-1A1 enzyme activity in neonates requires 2 dose changes over the first 6 weeks of life to meet efficacy and safety PK criteria.
Traditional paradigm of dose ranging followed by confirmatory study was changed into a single study in which M&S was used to integrate data to adapt dosing recommendations and update predictions.
$3-4 y by removing 1 study in a vulnerable population that would be very slowly in recruitment. Both company and regulator supported the use of modeling and simulation approaches, which resulted in shortened development time. informed selection of starting doses and trial designs leading to reduced burden on pediatric patients by optimizing the information gained in small sample sizes. These benefits are clearly demonstrable for drugs like raltegravir (for neonates), ivabradine (in pediatrics), and eslicarbazepine acetate (ESL, for children 4-17 years). Consider the case of raltegravir, an antiretroviral to treat HIV infections, which is in development for the neonatal population. Neonates undergo dramatic changes in metabolic enzyme maturation in their first weeks of life. In an adaptive design, with very limited pharmacokinetic (PK) data in a small number of neonates, the PK profiles of neonates after dosing were modeled to quantify and understand the impact of a dramatic age-related change in clearance of raltegravir. With this understanding, the team proposed two changes in dose regimen to achieve the desired exposure in newborns. This approach abrogated the need for sequential dose-ranging and confirmatory studies which typically take 3-4 years to complete. Thus, an integrative model-informed approach accelerated the availability of treatment for a vulnerable population that is extremely difficult to study using traditional clinical trial designs.
A similar example with ivabradine shows that modeling defined a lower weightnormalized starting dose in younger children suffering from chronic heart failure based on drug exposure, avoiding the risk of bradycardia related to supratherapeutic exposure. In older children, a higher weightnormalized dose with quicker titration was selected that avoided a lengthier study with unnecessary periods of ineffective subtherapeutic exposure.
For eslicarbazepine acetate, a modeling and simulation approach was made to gain approval for use in the pediatric population ranging from 4-17 years through extrapolation of drug exposures. After determining the pharmacokinetics in children, the team predicted the dosing regimen that provides similar drug exposure in pediatric patients 4 years of age and older and in adult patients with Partial Onset Seizures (POS). In such a way, this modeling replaced an independent pediatrics efficacy study, and thereby allowed earlier access for pediatric patients with POS.
In an era where serving the pediatric population is of utmost importance, these examples demonstrate how quantitative pharmacology can help us fulfill that goal more rapidly, while reducing the risk of either over-or underdosing these vulnerable patients in the context of the study.
SIMPLIFIED DOSING FOR PATIENTS AND HEALTHCARE PROVIDERS
QP has been instrumental in simplifying dosing for both patients and healthcare providers. For example, the flat dosing regimen for nivolumab, a fully-human anti-PD1 monoclonal antibody for the treatment of a variety of cancers, shortens drug preparation time and improves ease of administration. Integrated modeling and simulation of phase I-III data played a critical role in demonstrating that the antitumor activity plateaued at 3 mg/kg, and that the initially approved 3 mg/kg Q2W body weight-based dosing could be safely replaced with a 240 mg nivolumab flat dose without generating new clinical data. The approval of the flat dose resulted in self-estimated savings of $2 years in bringing simplified prescribing, shortened manufacturing time, and, most important, ease of administration to patients and healthcare providers for several cancer indications. As with other examples, this work required proactive planning and a clear understanding of the PK properties of the drug, together with the relationship of exposure to both efficacy and tolerability.
Similarly, modeling of early clinical data for ixazomib, an oral agent for the treatment of multiple myeloma, showed that there was no relationship between clearance and body surface area (BSA), suggesting that a fixed dose could be more appropriate. Based on these findings, phase III studies were conducted with a fixed dose, ultimately reflected in global labeling.
Thus, QP has played a key role in simplified dosing for multiple drugs across a variety of indications, leading to reduced pill burden for patients (for oral therapies) and potentially lower dosing errors through simplification of infusion preparation for healthcare providers. Moreover, both examples also helped challenge the established belief of BSA or a body weight-based dose being the norm in oncology-a paradigm shift that may further accelerate simplified treatment options for cancer patients.
